Emine Budak, Mehmet Ozeren, Gokhan Tosun, Abdurrahman Hamdi Inan, Ahkam Goksel Kanmaz, Emrah Beyan, Adnan Budak, Alper Ileri, Onur Suleyman Aldemir

The value of posttreatment CA125 and PET/CT in predicting prognosis of epithelial ovarian cancer

Aim: To investigate the association between post treatment F-18 fluorodeoxyglucose (FDG) positron emission tomography/ computed tomography (PET/CT) and post treatment cancer antigen 125 (CA125) results and overall survival (OS) of patients with epithelial ovarian cancer (EOC). Material and Methods: Survival was analyzed with Kaplan-Meier, Log-Rank and Cox proportional-hazards regression analyses. All cases and PET+ cases were evaluated separately. In addition, PET and CA125 results were evaluated together in the overall case group, and a survival analysis was made for the four defined groups. Results: The mean age of the 112 EOC-diagnosed patients was 54.9±0.9 years. Based on the PET/CT results, 48 patients were PETand 64 patients were PET+; and 59 patients were CA125- and 53 patients were CA125+. In the overall case group, OS was found to be significantly shorter in advanced stage patients when compared to the early stage patients, in the CA125+ patients when compared to the CA125- patients, and in the PET+ patients when compared to the PET- patients. A univariate analysis revealed a significant association between stage, CA125 and PET results, and OS. In a multivariate analysis, the association between stage and CA125 with OS was maintained, although the PET results were not significant. When the PET and CA125 results were evaluated together, the OS was significantly shorter in the CA125+/PET+ group than in the CA125-/PET-and CA125-/PET+ groups. In the PET+ group, CA125 and the time from diagnosis to positive PET result were identified as independent prognostic factors. Conclusion: Although OS had a tendency to be poorer in PET+ cases than negative cases, the PET results were not established as an independent prognostic factor for survival. Our findings suggest that the post treatment CA125 value is more beneficial than PET results for the estimation of prognosis in EOC.

PDF

___

1. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394-424.
2. Palomar A, Nanni C, Castellucci P, et al. Value of FDG PET/CT in patients with treated ovarian cancer and raised CA125 serum levels. Mol Imaging Biol 2012;14:123-9.
3. Morgan Jr RJ, Alvarez RD, Armstrong DK, et al. Epithelial ovarian cancer. J Natl Compr Canc Netw 2011;9:82-113.
4. Son H, Khan SM, Rahaman J, et al. Role of FDG PET/CT in staging of recurrent ovarian cancer. Radiographics 2011;31:569-83.
5. Huy NVQ, Van Khoa V, Tam LM, et al. Standard and optimal cut-off values of serum ca-125, HE4 and ROMA in preoperative prediction of ovarian cancer in Vietnam. Gynecol Oncol Rep 2018;25:110-4.
6. Rustin GJ, Nelstrop AE, Tuxen MK, et al. Defining Progression of Ovarian Carcinoma During Follow-up According to Ca 125: A North Thames Ovary Group Study. Ann Oncol 1996;7:361-4.
7. Evangelista L, Palma MD, Gregianin M,et al. Diagnostic and prognostic evaluation of fluorodeoxyglucose positron emission tomography/computed tomography and its correlation with serum cancer antigen-125 (CA125) in a large cohort of ovarian cancer patients. J Turk Ger Gynecol Assoc 2015;16:137-44.
8. Jacobs I, Bast RC Jr. The CA125 tumour-associated antigen: a review of the literature. Hum Reprod 1989;4:1-12
9. Gallicchio R, Nardelli A, Venetucci A, et al. F-18 FDG PET/CT metabolic tumor volume predicts overall survival in patients with disseminated epithelial ovarian cancer. Eur J Radiol 2017;93:107-13.
10. Musto A, Grassetto G, Marzola MC, et al. Management of epithelial ovarian cancer from diagnosis to restaging: an overview of the role of imaging techniques with particular regard to the contribution of 18F-FDG PET/ CT. Nucl Med Commun 2014;35:588-97.
11. Ledermann JA, Raja FA, Fotopoulou C, et al; ESMO Guidelines Working Group. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013;24:24-32.
12. Bast RC Jr, Klug TL, St. John E, et al. A radioimmunoassay using a monoclonal antibody monitor the course of epithelial ovarian cancer. New Engl J Med 1983;309: 883-7.
13. Durmus Y, Meydanli MM. Risk of Malignancy Index Has a Poor Sensitivity in Detecting Borderline Epithelial Tumors and Non-Epithelial Ovarian Tumors. Gynecol Obstet Reprod Med 2019;25:101-6.
14. Barut F, Barut A, Kertis G, et al. Distribution of Ovarian Tumors in Zonguldak Karaelmas University Hospital. Between 2001 and 2007. Gynecol Obstet Reprod Med 2008;14:36-40.
15. du Bois A, Reuss A, Pujade-Lauraine E, et al. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO). Cancer 2009;115:1234- 44.
16. Kurosaki H, Oriuchi N, Okazaki A, et al. Prognostic value of FDG-PET in patients with ovarian carcinoma following surgical treatment. Ann Nucl Med 2006;20:171-4.
17. Chu LC, Tsai HL, Wang H, et al. Posttreatment FDG PET/CT in predicting survival of patients with ovarian carcinoma. EJNMMI Res 2016;6:42.
18. Caobelli F, Alongi P, Evangelista L, et al. Predictive value of (18)F-FDG PET/CT in restaging patients affected by ovarian carcinoma: a multicentre study. Eur J Nucl Med Mol Imaging 2016;43:404-13.
19. Sala E, Kataoka M, Pandit-Taskar N, et al. Recurrent Ovarian Cancer: use of contrast-enhanced CT and PET/CT to accurately localize tumor recurrence and to predict patients’ survival. Radiology 2010;257:125- 34.
20. Liao S, Lan X, Cao G, et al. Prognostic predictive value of total lesion glycolysis from 18F-FDG PET/CT in post-surgical patients with epithelial ovarian cancer. Clin Nucl Med 2013;38:715-20.
21. Gadducci A, Iacconi P, Cosio S, et al. Complete salvage surgical cytoreduction improves further survival of patients with late recurrent ovarian cancer. Gynecol Oncol 2000;79:344-9.